The objective of this Phase III clinical trial was to assess the safety and efficacy of the UVAR photopheresis system in conjunction with UVADEX (liquid 8-methoxypsoralen) in the treatment of the skin manifestations of patients with early onset progressive systemic sclerosis (PSS). This was a multicenter clinical trial which was randomized and double-blinded and had a control (placebo) photopheresis treatment arm. Each eligible patient with signed informed consent was admitted to the General Clinical Research Center; a total of 10 patients enrolled in the study. Five patients completed the study and 5 withdrew from the study. Four of these 5 patients withdrew due to lack of clinical response or disease progression and the fifth patient withdrew due to the onset of a new medical illness which was considered unrelated to her PSS and her treatments. The efficacy and the summary of safety results will be available when the data from the last patients in all centers are collected. The study achieved its necessary enrollement goal for statistical analysis, and thus, it was closed to any new enrollement early in 1996.
Showing the most recent 10 out of 589 publications